Ruth M. O'Regan
Executive Vice Dean and Chief Academic Officer
Credentials: · · · · ·
History
- Present
UR School of Medicine and Dentistry
- Present
UR School of Medicine and Dentistry
- Present
UR School of Medicine and Dentistry
- 1994–1995
- 1992–1994
Mater Misericordiae University Hospital
- 1991–1992
BayCare Mease Hospital Dunedin
- 1988–1991
Mater Misericordiae University Hospital
Research
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 711 citations
Journal of Clinical Oncology · 2020 · 452 citations
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Review · Therapeutic Advances in Medical Oncology · 2014 · 444 citations
18 papers · 2 as a fellow
15 papers
14 papers
12 papers
10 papers
9 papers
8 papers · 3 as a resident
- SG
8 papers
Grants
- 2025–2030
University of Rochester Wilmot Cancer Institute Support Grant
National Cancer Institute · P30
Project lead · $355.3K · University of Rochester
- 2024–2029
Future Deaf Scientists Program at Wilmot Cancer Institute
National Cancer Institute · R25
Contact PI · $788.2K · University of Rochester
- 2015–2021
Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
National Cancer Institute · U01
PI · $3.3M · Beckman Research Institute/City of Hope
Clinical trials
- 2022–2027
Principal investigator · Recruiting · Phase 2
Ruth O'Regan
- 2010–2014
Re-expression of ER in Triple Negative Breast Cancers
Principal investigator · Terminated · Phase 1, Phase 2
Emory University
- 2008–2011
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Principal investigator · Completed · Phase 2
Emory University
- 2006
Principal investigator · Unknown · Phase 2
Georgia Center for Oncology Research & Education